PsyBio Therapeutics Corp.
PSYBF · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $2,564 | $6,499 | $1,655 | $10,516 |
| - Cash | $12 | $69 | $1 | $181 |
| + Debt | $96 | $96 | $135 | $172 |
| Enterprise Value | $2,647 | $6,526 | $1,790 | $10,507 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$25 | -$13 | -$38 | -$13 |
| % Margin | – | – | – | – |
| EBITDA | -$163 | -$770 | -$899 | -$878 |
| % Margin | – | – | – | – |
| Net Income | -$182 | -$811 | -$942 | -$922 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.001 | -0.01 | -0.015 | -0.008 |
| % Growth | 86% | 33.3% | -80.7% | – |
| Operating Cash Flow | $340 | -$355 | -$166 | -$708 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $340 | -$355 | -$166 | -$708 |